Get the Stockscreener App
2.4999
6.38%
+0.1499
After Hours:
2.50
0.0001
+0.00%
XORTX Therapeutics Inc. stock is currently priced at $2.4999, with a 24-hour trading volume of 7,384.
It has seen a +6.38% increased in the last 24 hours and a -21.14% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.40 pivot point. If it approaches the $2.55 resistance level, significant changes may occur.
Previous Close:
$2.35
Open:
$2.49
24h Volume:
7,384
Market Cap:
$7.26M
Revenue:
-
Net Income/Loss:
$-6.71M
P/E Ratio:
-5.7075
EPS:
-0.438
Net Cash Flow:
$-8.81M
1W Performance:
-0.80%
1M Performance:
-21.14%
6M Performance:
-16.67%
1Y Performance:
+257.13%
1D Range:
$2.3101
$2.54
52W Range:
$0.2498
$7.00
XORTX Therapeutics Inc. Stock (XRTX) Company Profile
Name
XORTX Therapeutics Inc.
Sector
Industry
Phone
-
Address
421 – 7th Avenue SW, Suite 4000, Vancouver
XORTX Therapeutics Inc. Stock (XRTX) Latest News
Closing Bell: Xortx Therapeutics Inc up on Wednesday (XRTX) - The Globe and Mail
The Globe and Mail
Closing Bell: Xortx Therapeutics Inc flat on Friday (XRTX) - The Globe and Mail
The Globe and Mail
Closing Bell: Xortx Therapeutics Inc down on Thursday (XRTX) - The Globe and Mail
The Globe and Mail
XORTX amends warrant terms, adds acceleration clause - Investing.com India
Investing.com India
XORTX amends warrant terms, adds acceleration clause - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
XORTX amends warrant terms, adds acceleration clause By Investing.com - Investing.com
Investing.com
XORTX Therapeutics Inc. Stock (XRTX) Financials Data
XORTX Therapeutics Inc. (XRTX) Net Income 2024
XRTX net income (TTM) was -$6.71 million for the quarter ending September 30, 2023, a -437.09% decrease year-over-year.
XORTX Therapeutics Inc. (XRTX) Cash Flow 2024
XRTX recorded a free cash flow (TTM) of -$8.81 million for the quarter ending September 30, 2023, a -3.67% decrease year-over-year.
XORTX Therapeutics Inc. (XRTX) Earnings per Share 2024
XRTX earnings per share (TTM) was -$3.6185 for the quarter ending September 30, 2023, a -198.69% decline year-over-year.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
0.77%
1.20%
Cap:
|
Volume (24h):